{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:36:49Z","timestamp":1790660209881,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012304","name":"Johns Hopkins School of Medicine","doi-asserted-by":"publisher","award":["5P30CA006973-52"],"award-info":[{"award-number":["5P30CA006973-52"]}],"id":[{"id":"10.13039\/100012304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012304","name":"Johns Hopkins School of Medicine","doi-asserted-by":"publisher","award":["P50CA58236"],"award-info":[{"award-number":["P50CA58236"]}],"id":[{"id":"10.13039\/100012304","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016737","name":"Patrick C. Walsh Prostate Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jmoldx.2021.05.006","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T11:21:48Z","timestamp":1622287308000},"page":"1030-1041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Assessment of MYC\/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1904-185X","authenticated-orcid":false,"given":"Daniela C.","family":"Salles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago","family":"Vidotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana A.","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Tosoian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana B.","family":"Guedes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-8225","authenticated-orcid":false,"given":"Andrea","family":"Muranyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-5292","authenticated-orcid":false,"given":"Shalini","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandavel","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara L.","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2021.05.006_bib1","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.juro.2016.06.102","article-title":"Active surveillance for intermediate risk prostate cancer: survival outcomes in the sunnybrook experience","volume":"196","author":"Musunuru","year":"2016","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.jmoldx.2021.05.006_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5858\/arpa.2020-0015-RA","article-title":"The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer","volume":"145","author":"Epstein","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib3","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/modpathol.2016.49","article-title":"Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy","volume":"29","author":"Kweldam","year":"2016","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.jmoldx.2021.05.006_bib4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41379-020-0625-x","article-title":"Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients","volume":"34","author":"Hollemans","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.eururo.2019.07.051","article-title":"Improved prostate cancer biopsy grading by incorporation of invasive cribriform and intraductal carcinoma in the 2014 Grade Groups","volume":"77","author":"van Leenders","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/modpathol.2015.146","article-title":"The presence of intraductal carcinoma of the prostate in needle biopsy is a significant prognostic factor for prostate cancer patients with distant metastasis at initial presentation","volume":"29","author":"Kato","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib7","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAS.0000000000001450","article-title":"Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers, I: molecular biomarkers in prostate cancer","volume":"44","author":"Lotan","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/pcan.2015.31","article-title":"Which, when and why? rational use of tissue-based molecular testing in localized prostate cancer","volume":"19","author":"Ross","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib9","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/j.clgc.2016.08.012","article-title":"Cost-effectiveness of the Decipher genomic classifier to guide individualized decisions for early radiation therapy after prostatectomy for prostate cancer","volume":"15","author":"Lobo","year":"2017","journal-title":"Clin Genitourinary Cancer"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib10","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1158\/1078-0432.CCR-11-1244","article-title":"PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients","volume":"17","author":"Lotan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib11","article-title":"A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer","volume":"108","author":"Ahearn","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib12","first-page":"904","article-title":"Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH","volume":"29","author":"Lotan","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat Reviews Urol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib14","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/modpathol.2016.63","article-title":"PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance","volume":"29","author":"Trock","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib15","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/j.humpath.2013.01.012","article-title":"8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy","volume":"44","author":"Fromont","year":"2013","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1746-1596-7-60","article-title":"A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections","volume":"7","author":"Nitta","year":"2012","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.juro.2016.09.084","article-title":"PTEN loss in Gleason score 3 + 4 = 7 prostate biopsies is associated with nonorgan confined disease at radical prostatectomy","volume":"197","author":"Guedes","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib18","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1097\/PAS.0b013e3182217b79","article-title":"Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? correlation with radical prostatectomy findings","volume":"35","author":"Karram","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib19","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.jmoldx.2021.05.006_bib20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.euf.2015.07.005","article-title":"PTEN loss as determined by clinical-grade immunohistochemistry assay is associated with worse recurrence-free survival in prostate cancer","volume":"2","author":"Lotan","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3324\/haematol.2009.012864","article-title":"Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma","volume":"95","author":"Stasik","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bju.14655","article-title":"An updated approach to incremental nerve sparing for robot-assisted radical prostatectomy","volume":"124","author":"Martini","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","article-title":"Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores","volume":"61","author":"Briganti","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.juro.2018.10.023","article-title":"Clinical, pathological and oncologic findings of radical prostatectomy with extraprostatic extension diagnosed on preoperative prostate biopsy","volume":"201","author":"Faisal","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","article-title":"Accuracy of magnetic resonance imaging for local staging of prostate\u00a0cancer: a diagnostic meta-analysis","volume":"70","author":"de Rooij","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib26","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline, part I: risk stratification, shared decision making, and care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s12032-018-1212-6","article-title":"Association of ERG\/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer","volume":"35","author":"Mehra","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1464-410X.2010.09470.x","article-title":"PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer","volume":"107","author":"Bismar","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib29","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6603924","article-title":"FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome","volume":"97","author":"Yoshimoto","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib30","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.eururo.2018.08.020","article-title":"Comparing prognostic utility of a single-marker immunohistochemistry approach with commercial gene expression profiling following radical prostatectomy","volume":"74","author":"Leapman","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib31","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6605554","article-title":"Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer","volume":"102","author":"Reid","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib32","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1158\/1078-0432.CCR-05-1977","article-title":"8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects","volume":"12","author":"Ribeiro","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib33","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1002\/cncr.26729","article-title":"Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy","volume":"118","author":"Zafarana","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jmoldx.2021.05.006_bib34","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/JU.0000000000001290","article-title":"The prognostic impact of intraductal carcinoma of the prostate: a systematic review and meta-analysis","volume":"204","author":"Miura","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib35","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/modpathol.2017.29","article-title":"Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer","volume":"30","author":"Kweldam","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib36","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1097\/JU.0000000000000316","article-title":"Impact of cribriform pattern and intraductal carcinoma on gleason 7 prostate cancer treated with external beam radiotherapy","volume":"202","author":"Tom","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00428-015-1809-5","article-title":"Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy","volume":"467","author":"Keefe","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib38","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/his.13427","article-title":"Characteristics and outcome of prostate cancer patients with overall biopsy Gleason score 3 + 4 = 7 and highest Gleason score 3 + 4 = 7 or > 3 + 4 = 7","volume":"72","author":"Verhoef","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1309\/AJCPZ7WBU9YXSJPE","article-title":"Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome","volume":"136","author":"Iczkowski","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib40","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/PAS.0000000000000736","article-title":"Histologic grading of prostatic adenocarcinoma can be further optimized: analysis of the relative prognostic strength of individual architectural patterns in 1275 patients from the canary retrospective cohort","volume":"40","author":"McKenney","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib41","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.ejca.2014.03.009","article-title":"Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort","volume":"50","author":"Trudel","year":"2014","journal-title":"Eur Journal Cancer"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41379-018-0157-9","article-title":"Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis","volume":"32","author":"Hollemans","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib43","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/pros.23977","article-title":"Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4","volume":"80","author":"Greenland","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.jmoldx.2021.05.006_bib44","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/jnci\/djm169","article-title":"Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans","volume":"99","author":"Zheng","year":"2007","journal-title":"J Natl Cancer Inst"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157821001331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157821001331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:16:23Z","timestamp":1761502583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157821001331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1525157821001331"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2021.05.006","relation":{},"ISSN":["1525-1578"],"issn-type":[{"value":"1525-1578","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of MYC\/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2021.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}